secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0000950170-24-074243
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics stockholders elect Pratik Shah as Class III director, ratify EY auditor
--------------------------------------------------------------------------------

- Pratik Shah, Ph.D. elected as Class III director with ~42.8M votes for, ~3.5M withheld (7.7M broker non-votes).
- Ernst & Young LLP ratified as independent auditor for FY2024 (53,981,806 for, 2,764 against, 2 abstentions).
- Annual Meeting held June 13, 2024; 56,495,039 shares outstanding and entitled to vote as of record date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017024074243/0000950170-24-074243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017024074243/dsgn-20240613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-074243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer